Skip to content

EBITDA at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.67M+30.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$30.2M+63.9%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.05M-23.8%
Incyte logo
IncyteINCY
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%
Enterprise value$1.73B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Calculated from Tyra Biosciences, Inc.’s reported figures.

$42.0Mebit+
$138.0KDepreciation Depletion & Amortization
=-$41.86M

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s EBITDA?
Tyra Biosciences, Inc. (TYRA) reported EBITDA of -$41.86M in Q1 2026.
How has Tyra Biosciences, Inc.'s EBITDA changed year-over-year?
Tyra Biosciences, Inc.'s EBITDA decreased by 32.0% year-over-year, from -$31.71M to -$41.86M.
What is the long-term trend for Tyra Biosciences, Inc.'s EBITDA?
Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s EBITDA has grown at a 50.0% compound annual growth rate (CAGR), from -$26.15M to -$132.22M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.